These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Tocilizumab versus adalimumab for rheumatoid arthritis. De Vita S Lancet; 2013 May; 381(9877):1515-7. PubMed ID: 23642688 [No Abstract] [Full Text] [Related]
7. Sarilumab (Kevzara) for rheumatoid arthritis. Med Lett Drugs Ther; 2017 Aug; 59(1527):134-136. PubMed ID: 28787744 [No Abstract] [Full Text] [Related]
8. IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. Tanaka Y; Martin Mola E Ann Rheum Dis; 2014 Sep; 73(9):1595-7. PubMed ID: 24833786 [No Abstract] [Full Text] [Related]
9. Rheumatoid arthritis: IL-6 inhibition in RA--déjà vu all over again? Ruderman EM Nat Rev Rheumatol; 2015 Jun; 11(6):321-2. PubMed ID: 25907702 [No Abstract] [Full Text] [Related]
10. Comment on: tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice. Besada E Rheumatology (Oxford); 2015 Apr; 54(4):751. PubMed ID: 25602064 [No Abstract] [Full Text] [Related]
11. [Rheumatoid Arthritis - New Treatment Options]. Fiehn C Dtsch Med Wochenschr; 2017 Dec; 142(24):1844-1848. PubMed ID: 29207429 [No Abstract] [Full Text] [Related]
12. Comment on "Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks" by Yokoe et al. Nagashima T; Okazaki H; Kamata Y; Minota S Mod Rheumatol; 2012 Aug; 22(4):638-9; authoe reply 640-2. PubMed ID: 22669601 [No Abstract] [Full Text] [Related]
14. Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study. Sanmarti R; Inciarte-Mundo J; Estrada-Alarcon P; Garcia-Manrique M; Narvaez J; Rodriguez-Moreno J; Gomez-Centeno A; Pascal M; Yagüe J Ann Rheum Dis; 2015 Aug; 74(8):e42. PubMed ID: 25805737 [No Abstract] [Full Text] [Related]
15. Problems with ethical approval and how to fix them: lessons from three trials in rheumatoid arthritis. Mendel J; Goldacre B; Ernst E; Whittle S BMJ; 2016 Sep; 354():i4626. PubMed ID: 27613703 [No Abstract] [Full Text] [Related]
16. Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks. Yokoe I; Nishio S; Sato H; Kobayashi H Mod Rheumatol; 2011 Dec; 21(6):710-4. PubMed ID: 21656090 [No Abstract] [Full Text] [Related]
17. Kinase inhibition--a new approach to the treatment of rheumatoid arthritis. Fox DA N Engl J Med; 2012 Aug; 367(6):565-7. PubMed ID: 22873537 [No Abstract] [Full Text] [Related]
18. Towards an individualised target concentration of adalimumab in rheumatoid arthritis. Ducourau E; Ternant D; Lequerré T; Fuzibet P; Le Loët X; Watier H; Goupille P; Paintaud G; Vittecoq O; Mulleman D Ann Rheum Dis; 2014 Jul; 73(7):1428-9. PubMed ID: 24550169 [No Abstract] [Full Text] [Related]
19. Ups and downs in the treatment strategies of rheumatoid arthritis. Schipper LG; van Riel PL Rheumatology (Oxford); 2011 May; 50(5):818-20. PubMed ID: 20663813 [No Abstract] [Full Text] [Related]
20. Subclinical inflammation with tocilizumab treatment of rheumatoid arthritis: MRI evaluation for 2 years. Suzuki T; Hirota T; Ogishima H; Umeda N; Kondo Y; Yokosawa M; Miki H; Tsuboi H; Matsumoto I; Sumida T Int J Rheum Dis; 2015 Jan; 18(1):108-10. PubMed ID: 25294091 [No Abstract] [Full Text] [Related] [Next] [New Search]